Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Imagion Biosystems Ltd. (AU:IBX)
ASX:IBX
Holding AU:IBX?
Track your performance easily
IBX Stock Chart & Stats
Day’s RangeAU$0 - AU$0
52-Week RangeAU$0.02 - AU$0.48
Previous CloseAU$0.05
Volume15.00K
Average Volume (3M)256.68K
Market Cap
AU$2.24M
Enterprise ValueAU$2.40M
Total Cash (Recent Filing)AU$4.45M
Total Debt (Recent Filing)AU$4.60M
Price to Earnings (P/E)―
Beta-1.22
Next Earnings
Feb 27, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.19
Shares Outstanding29,191,644
10 Day Avg. Volume523,537
30 Day Avg. Volume256,677
Standard Deviation0.30
R-Squared0.15
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)0.00
Price to Sales (P/S)10.42
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
Imagion Biosystems Ltd. News
PremiumCompany Announcements
Imagion Biosystems Boosts Funding and Secures Licensing Deal
PremiumCompany Announcements
Imagion Biosystems Ltd. Seeks ASX Quotation for New Securities
PremiumCompany Announcements
Imagion Biosystems Announces Share Placement Strategy
PremiumCompany Announcements
Imagion Biosystems Corrects Securities Placement Details
PremiumCompany Announcements
Imagion Biosystems Offers Shares, Cautions InvestorsPremiumCompany Announcements
Imagion Biosystems Plans Major Securities Issue
PremiumCompany Announcements
Imagion Biosystems Unveils Cancer Detection BreakthroughPremiumCompany Announcements
Imagion Biosystems Raises A$3M for Cancer TechOptions Prices
Currently, No data available
---
Ownership Overview
IBX FAQ
What was Imagion Biosystems Ltd.’s price range in the past 12 months?
Imagion Biosystems Ltd. lowest share price was AU$0.02 and its highest was AU$0.48 in the past 12 months.
What is Imagion Biosystems Ltd.’s market cap?
Currently, no data Available
When is Imagion Biosystems Ltd.’s upcoming earnings report date?
Imagion Biosystems Ltd.’s upcoming earnings report date is Feb 27, 2025 which is in 114 days.
How were Imagion Biosystems Ltd.’s earnings last quarter?
Imagion Biosystems Ltd. released its earnings results on Aug 30, 2024. The company reported -AU$0.047 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.047.
Is Imagion Biosystems Ltd. overvalued?
According to Wall Street analysts Imagion Biosystems Ltd.’s price is currently Overvalued.
Does Imagion Biosystems Ltd. pay dividends?
Imagion Biosystems Ltd. does not currently pay dividends.
What is Imagion Biosystems Ltd.’s EPS estimate?
Imagion Biosystems Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Imagion Biosystems Ltd. have?
Imagion Biosystems Ltd. has 43,038,666 shares outstanding.
What happened to Imagion Biosystems Ltd.’s price movement after its last earnings report?
Imagion Biosystems Ltd. reported an EPS of -AU$0.047 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Imagion Biosystems Ltd.?
Currently, no hedge funds are holding shares in AU:IBX
---
Imagion Biosystems Ltd. Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-88.18%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-90.78%
Trailing 12-Months
Company Description
Imagion Biosystems Ltd.
Imagion Biosystems Ltd operates in the field of non-invasive detection of specific solid tumor cancers by use of magnetic nanoparticles. The company only operating segment - Research and Development. Its principal business activities consist of nanotechnology, biotechnology, cancer diagnostics, and superparamagnetic relaxometry. In addition, the company is engaged in the research and development of its clinical phase lead product which is intended for the detection and staging of metastatic HER2 breast cancer.
---
Technical Analysis
Race Oncology Ltd.
―
Holista Colltech Limited
―
Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
―
LBT Innovations Limited
―
---